FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Ji Henry 2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [ SRNE ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)         (First)         (Middle)
C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE
3. Date of Earliest Transaction (MM/DD/YYYY)
6/15/2020
(Street)
SAN DIEGO, CA 92121
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options  $4.89  6/15/2020    A     1500000       (1) 6/15/2030  Common Stock  1500000.0  $0  1500000  D   

Explanation of Responses:
(1)  1/4th of the original number of shares subject to the option shall vest on June 15, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after June 15, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Remarks:
President, CEO and Chairman of the Board of Directors

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ji Henry
C/O SORRENTO THERAPEUTICS, INC.
4955 DIRECTORS PLACE
SAN DIEGO, CA 92121
X
See Remarks

Signatures
/s/ Henry Ji, Ph.D. 6/15/2020
**Signature of Reporting Person Date
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Sorrento Therapeutics Charts.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Sorrento Therapeutics Charts.